Ratings for Alnylam Pharmaceuticals ALNY -1.28% Get Free Report were provided by 18 analysts in the past three months, ...

Alnylam Pharmaceuticals, Inc. ALNY announced that the European Commission (EC) has approved a label expansion of its RNAi ...

A local pharmaceutical company has been awarded $1.8 million through a state tax incentive program aimed at creating more ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 13 Biotech Stocks with Huge Upside Potential. It declared on June 9 ...

A local pharmaceutical company has been awarded $1.8 million through a state tax incentive program aimed at creating more ...

Amvuttra is the first and only RNA interference (RNAi) therapeutic approved by the EC for both the cardiomyopathy and the ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the European Commission (EC) to treat adults with ...

Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

H.C. Wainwright’s Patrick Trucchio reiterated his Buy rating on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and raised his ...

Moderna convinced a U.S. appeals court on Wednesday to uphold a ruling that undercut patent infringement claims by biotech ...

Biotechnology Innovation Organization trade show is expected to bring about 20,000 participants to Boston starting on Monday.